ReviewJournal of ophthalmic inflammation and infection2025
Scleritis and associated systemic diseases: contribution of systemic examination, follow-up, and additional investigations.
Review in Journal of ophthalmic inflammation and infection, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundIdentifying underlying disease associations in patients with scleritis remains a clinical challenge. This study aimed to assess the contribution of systemic examination, longitudinal follow-up, and additional investigations to the identification of associated diseases in patients with scleritis.
methodsWe retrospectively reviewed 98 patients with scleritis in whom no associated disease had been identified at presentation, assessed in two internal medicine departments in Lyon between July 2011 and September 2023. Data were collected at the initial presentation, prior to the identification of any underlying disease. The primary outcome was the contribution of systemic examination to the identification of associated diseases.
resultsAfter a median follow-up of 42 months [15.5-100], an associated disease was identified in 37 patients (37.8%), including 23 systemic diseases (23.5%), 12 infectious diseases (12.2%), and 2 cases of drug-induced scleritis (2.0%). Systemic examination contributed to the identification of an associated disease in 20 patients (20.4%), mainly through ear, nose and throat (ENT) and dermatological assessments. In 70% of these patients, systemic manifestations preceded the first episode of scleritis, while in the remaining 30% they developed during follow-up. In three patients, scleritis was the initial and sole manifestation, and the diagnosis was established through additional investigations during follow-up. The positive predictive value (PPV) of non-specific anti-neutrophil cytoplasmic antibodies (ANCA) was 29%, with a negative predictive value (NPV) of 98%. When specific ANCA testing was performed, the PPV increased to 86%. Repeating laboratory investigations during follow-up did not yield additional diagnoses.
conclusionSystemic examination contributed to the identification of an associated disease in one-fifth of patients. Scleritis may be the first clinical manifestation of an underlying systemic disease, supporting the need for systematic and prolonged follow-up. These findings also underline the diagnostic value of specific ANCA testing, whereas repeating laboratory investigations after an initial negative assessment appears of limited utility.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.